Treating disorders across the lifespan by modulating cholinergic signaling with galantamine
Open Access
- 20 November 2020
- journal article
- review article
- Published by Wiley in Journal of Neurochemistry
- Vol. 158 (6) , 1359-1380
Abstract
Advances in understanding the regulatory functions of the nervous system have revealed neural cholinergic signaling as a key regulator of cytokine responses and inflammation. Cholinergic drugs, including the centrally acting acetylcholinesterase inhibitor, galantamine, which are in clinical use for the treatment of Alzheimer's disease and other neurodegenerative and neuropsychiatric disorders, have been rediscovered as anti‐inflammatory agents. Here, we provide a timely update on this active research and clinical developments. We summarize the involvement of cholinergic mechanisms and inflammation in the pathobiology of Alzheimer's disease, Parkinson's disease, and schizophrenia, and the effectiveness of galantamine treatment. We also highlight recent findings demonstrating the effects of galantamine in preclinical and clinical settings of numerous conditions and diseases across the lifespan that are characterized by immunological, neurological, and metabolic dysfunction. imageKeywords
Funding Information
- National Institute of General Medical Sciences (R01GM121102, R01GM128008)
This publication has 232 references indexed in Scilit:
- Effectiveness of Donepezil, Rivastigmine, and (±)Huperzine A in Counteracting the Acute Toxicity of Organophosphorus Nerve Agents: Comparison with GalantamineThe Journal of Pharmacology and Experimental Therapeutics, 2009
- In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome modelNeurobiology of Aging, 2009
- Mammalian Nicotinic Acetylcholine Receptors: From Structure to FunctionPhysiological Reviews, 2009
- High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophreniaSchizophrenia Research, 2008
- Brain cholinergic impairment in liver failureBrain, 2008
- Neuro-immune interactions via the cholinergic anti-inflammatory pathwayLife Sciences, 2007
- Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in ratsNeuropharmacology, 2007
- Cholinergic Circuits and Signaling in the Pathophysiology of Schizophrenia2007
- Effective countermeasure against poisoning by organophosphorus insecticides and nerve agentsProceedings of the National Academy of Sciences, 2006
- Points of control in inflammationNature, 2002